Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance
In plain words A study of oroxylum indicum in people 40 to 80, run by SF Research Institute, Inc.. It plans to enroll about 140 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 80; healthy volunteers accepted. Conditions: Insulin Resistance; Mild Cognitive Impairment; Cognitive Decline; Neurodegenerative Disorders.
- Female or male, adults grouped by age as follows 2 groups of 70 patients each (35 active and 35 placebo )
- GROUP 1 = aged 40 - 60, and
- GROUP 2 = aged 61 - 80
- In good general health
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Sabroxy®; Placebo
Registered summary
This randomized, double-blind, placebo-controlled, 8-week clinical trial is designed to evaluate the effects of Sabroxy®, a standardized extract of Oroxylum indicum bark, on insulin resistance and cognitive function in adults with mild cognitive impairment and insulin resistance. A total of 120 participants (men and women, aged 40-80 years) who are non-smokers, with fasting glucose levels between 100-135 mg/dL, HOMA-IR value ≥ 2.0 to \< 4.0, and a Montreal Cognitive Assessment (MoCA) score below 26, will be enrolled. The full summary is on the listing.
Where, as registered
1 US site in 1 state.